Table 1. Patient demographic, clinical, and functional characteristics.
| Healthy | Smokers at risk | COPD | AATD (PiZZ) |
|
|---|---|---|---|---|
| Number | 5 | 6 | 3 | 3 |
| Gender (M, %) | 80 | 50 | 100 | 100 |
| Age (years) | 40 ± 11.3 | 37 ± 12.1 | 52 ± 3.7 | 53.5 ± 10.5 |
| Race (W, %) | 40 | 83 | 33 | 100 |
| Smoking status (ex-smoker/never smoker) | 0/2 | 6/0 | 2/1 | 2/1 |
| Smoking history (PY) | 1.5 ± 2 | 12.5 ± 4.5 | 29.3 ± 7 | 30 ± 21 |
| FEV1 (%predicted) | NA | NA | 73 ± 10.2 | 48.1 ± 14.2 |
| GOLD stage (0/1-2/3-4) | NA | 6/0/0 | 0/3/0 | 0/1/2 |
| A1AT (mg/dL) Visit 1 Visit 2 Visit 3 |
NA |
NA |
NA |
73.0 ± 5.0 126 ± 12.7 71.0 ± 6.1 |
| BAL fluid cell count (X107 cells/mL) | 2.6 ± 1.1 | 15.1 ± 10.3 | NA | NA |
Data are presented as mean ± SD or percentage (%). Abbreviations: AATD: alpha-1 antitrypsin deficiency; PiZZ—homozygous for A1AT gene Z mutation; PY: pack-year; FEV1: forced expiratory volume in 1 s; GOLD: the Global initiative for chronic Obstructive Lung Disease; A1AT: alpha-1 antitrypsin; BAL: broncho-alveolar lavage